Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04353492




Registration number
NCT04353492
Ethics application status
Date submitted
16/04/2020
Date registered
20/04/2020
Date last updated
23/04/2024

Titles & IDs
Public title
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Scientific title
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod
Secondary ID [1] 0 0
2019-001341-40
Secondary ID [2] 0 0
COMB157G23101
Universal Trial Number (UTN)
Trial acronym
ARTIOS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsing Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Ofatumumab

Experimental: Ofatumumab - Ofatumumab 20 mg subcutaneous injections every 4 weeks, following loading of 3 doses in the first 14 days


Other interventions: Ofatumumab
Subjects will receive ofatumumab injections in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annual Relapse Rate (ARR)
Timepoint [1] 0 0
Up to 96 weeks from baseline
Secondary outcome [1] 0 0
Safety evaluation
Timepoint [1] 0 0
96 weeks

Eligibility
Key inclusion criteria
- Diagnosis of MS according to the 2017 Revised McDonald criteria

- Relapsing MS: relapsing forms of MS (RMS) including RMS and secondary progressive MS
(SPMS)

- Disability status at screening defined by Expanded Disability Status Scale (EDSS)
score of 0 to 4 (inclusive)

- MS treatment history with a maximum of 3 Disease Modifying Therapies (DMTs), where all
fumarates are considered as one DMT

- Subject transitioning from either any fumarate-based RMS approved therapies, such as
dimethyl fumarate (DMF) or diroximel fumarate (DRF), or fingolimod which was
administered for a period of at least 6 months, as their last DMT before first study
drug administration

- Breakthrough disease activity while the participant was adequately using fumarates or
fingolimod prior to transitioning for a minimum of 6 months as evidenced by one or
more clinically reported relapses or one or more signs of Magnetic Resonance Imaging
(MRI) activity (e.g. Gd+ enhancement, new or enlarging T2 lesions)

- Neurologically stable within one month prior to first study drug administration
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Subjects with primary progressive MS or SPMS without disease activity

- Subjects meeting criteria for neuromyelitis optica

- Disease duration of more than 10 years since diagnosis

- Pregnant or nursing (lactating) women

- Women of child-bearing potential unless they are using highly effective forms of
contraception during dosing and for at least 6 months after stopping study medication

- Subjects with active chronic disease of the immune system other than MS or with
immunodeficiency syndrome

- Subjects with active systemic bacterial, fungal or viral infections (such as
hepatitis, HIV, COVID-19), or known to have Acquired Immunodeficiency Syndrome (AIDS)

- Subjects with neurological symptoms consistent with Progressive Multifocal
Leukoencephalopathy (PML) or with confirmed PML

- Subjects at risk of developing or having reactivation of syphilis or tuberculosis
(e.g. subjects with known exposure to, or history of syphilis, or active or latent
tuberculosis, even if previously treated), as confirmed by medical history or per
local practice

- Subjects with active hepatitis B and C disease, assessed locally

- Have received any live or live-attenuated vaccines within 4 weeks prior to first study
drug administration

- Have been treated with medications as specified or within timeframes specified (e.g.
corticosteroids, ofatumumab, rituximab, ocrelizumab, alemtuzumab, natalizumab,
daclizumab, cyclophosphamide, teriflunomide etc.)

- Subjects suspected of not being able or willing to cooperate or comply with study
protocol requirements in the opinion of the investigator

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/07/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
11/04/2025
Actual
Sample size
Target
Accrual to date
Final
564
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - New Lambton Heights
Recruitment hospital [2] 0 0
Novartis Investigative Site - Woolloongabba
Recruitment hospital [3] 0 0
Novartis Investigative Site - Parkville
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Delaware
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Nevada
Country [8] 0 0
United States of America
State/province [8] 0 0
New Mexico
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Oklahoma
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Virginia
Country [15] 0 0
United States of America
State/province [15] 0 0
Wisconsin
Country [16] 0 0
Argentina
State/province [16] 0 0
Santa Fe
Country [17] 0 0
Argentina
State/province [17] 0 0
Buenos Aires
Country [18] 0 0
Argentina
State/province [18] 0 0
Tucuman
Country [19] 0 0
Austria
State/province [19] 0 0
Oberoesterreich
Country [20] 0 0
Austria
State/province [20] 0 0
Linz
Country [21] 0 0
Austria
State/province [21] 0 0
Vienna
Country [22] 0 0
Austria
State/province [22] 0 0
Wien
Country [23] 0 0
Belgium
State/province [23] 0 0
Antwerpen
Country [24] 0 0
Belgium
State/province [24] 0 0
Brugge
Country [25] 0 0
Belgium
State/province [25] 0 0
Bruxelles
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Pleven
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Sofia
Country [28] 0 0
Canada
State/province [28] 0 0
Ontario
Country [29] 0 0
Czechia
State/province [29] 0 0
Czech Republic
Country [30] 0 0
Czechia
State/province [30] 0 0
CZE
Country [31] 0 0
Czechia
State/province [31] 0 0
Praha
Country [32] 0 0
Estonia
State/province [32] 0 0
Tallinn
Country [33] 0 0
Estonia
State/province [33] 0 0
Tartu
Country [34] 0 0
Germany
State/province [34] 0 0
Bielefeld
Country [35] 0 0
Germany
State/province [35] 0 0
Cottbus
Country [36] 0 0
Germany
State/province [36] 0 0
Heidelberg
Country [37] 0 0
Germany
State/province [37] 0 0
Koln
Country [38] 0 0
Germany
State/province [38] 0 0
Leipzig
Country [39] 0 0
Germany
State/province [39] 0 0
Muenchen
Country [40] 0 0
Germany
State/province [40] 0 0
Osnabrück
Country [41] 0 0
Germany
State/province [41] 0 0
Potsdam
Country [42] 0 0
Germany
State/province [42] 0 0
Siegen
Country [43] 0 0
Germany
State/province [43] 0 0
Ulm
Country [44] 0 0
Germany
State/province [44] 0 0
Westerstede Oldenburg
Country [45] 0 0
Greece
State/province [45] 0 0
GR
Country [46] 0 0
Greece
State/province [46] 0 0
Greece
Country [47] 0 0
Greece
State/province [47] 0 0
Thessaloniki
Country [48] 0 0
Hungary
State/province [48] 0 0
HUN
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Hungary
State/province [50] 0 0
Pecs
Country [51] 0 0
Italy
State/province [51] 0 0
FI
Country [52] 0 0
Italy
State/province [52] 0 0
PV
Country [53] 0 0
Italy
State/province [53] 0 0
RM
Country [54] 0 0
Italy
State/province [54] 0 0
VR
Country [55] 0 0
Latvia
State/province [55] 0 0
LV
Country [56] 0 0
Latvia
State/province [56] 0 0
Riga
Country [57] 0 0
Lebanon
State/province [57] 0 0
Ashrafieh
Country [58] 0 0
Lebanon
State/province [58] 0 0
Beirut
Country [59] 0 0
Mexico
State/province [59] 0 0
Distrito Federal
Country [60] 0 0
Mexico
State/province [60] 0 0
Michoacan
Country [61] 0 0
Norway
State/province [61] 0 0
Oslo
Country [62] 0 0
Poland
State/province [62] 0 0
Woj Kujawsko-pomorskie
Country [63] 0 0
Poland
State/province [63] 0 0
Katowice
Country [64] 0 0
Poland
State/province [64] 0 0
Kielce
Country [65] 0 0
Poland
State/province [65] 0 0
Lodz
Country [66] 0 0
Poland
State/province [66] 0 0
Wroclaw
Country [67] 0 0
Portugal
State/province [67] 0 0
Braga
Country [68] 0 0
Portugal
State/province [68] 0 0
Lisboa
Country [69] 0 0
Portugal
State/province [69] 0 0
Loures
Country [70] 0 0
Portugal
State/province [70] 0 0
Porto
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Moscow
Country [72] 0 0
Russian Federation
State/province [72] 0 0
St Petersburg
Country [73] 0 0
Saudi Arabia
State/province [73] 0 0
SAU
Country [74] 0 0
Saudi Arabia
State/province [74] 0 0
Jeddah
Country [75] 0 0
Slovakia
State/province [75] 0 0
Slovak Republic
Country [76] 0 0
Slovakia
State/province [76] 0 0
Banska Bystrica
Country [77] 0 0
Slovakia
State/province [77] 0 0
Bratislava
Country [78] 0 0
Slovakia
State/province [78] 0 0
Nitra
Country [79] 0 0
Slovakia
State/province [79] 0 0
Trnava
Country [80] 0 0
Slovenia
State/province [80] 0 0
Ljubljana
Country [81] 0 0
Slovenia
State/province [81] 0 0
Maribor
Country [82] 0 0
Spain
State/province [82] 0 0
Andalucia
Country [83] 0 0
Spain
State/province [83] 0 0
Cataluna
Country [84] 0 0
Spain
State/province [84] 0 0
Comunidad Valenciana
Country [85] 0 0
Spain
State/province [85] 0 0
Murcia
Country [86] 0 0
Spain
State/province [86] 0 0
Vizcaya
Country [87] 0 0
Spain
State/province [87] 0 0
Madrid
Country [88] 0 0
Spain
State/province [88] 0 0
Santa Cruz de Tenerife
Country [89] 0 0
Spain
State/province [89] 0 0
Valencia
Country [90] 0 0
Switzerland
State/province [90] 0 0
Basel
Country [91] 0 0
Turkey
State/province [91] 0 0
Istanbul
Country [92] 0 0
Turkey
State/province [92] 0 0
TUR
Country [93] 0 0
Turkey
State/province [93] 0 0
Izmir
Country [94] 0 0
Turkey
State/province [94] 0 0
Samsun
Country [95] 0 0
Turkey
State/province [95] 0 0
Trabzon
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Cardiff
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects
transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough
disease.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04353492
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04353492